The world's API powerhouse. Compare Indian CDMOs across API synthesis, oral solid dose, sterile fill-finish, and peptides — many FDA-inspected — by capability and site.
2 companies listed
India is the engine of global small-molecule API manufacturing, with one of the largest concentrations of FDA-inspected drug facilities outside the United States. Indian CDMOs supply APIs and finished generics to nearly every major market and typically offer a 30–50% cost advantage over Western alternatives for chemical synthesis.
Capability has moved well beyond commodity APIs. Leading Indian CDMOs now run sterile fill-finish, complex injectables, peptide synthesis (riding the GLP-1 wave), and high-potency manufacturing. Manufacturing clusters around Hyderabad, Bengaluru, Gujarat, and the Mumbai–Pune corridor each carry distinct specializations.
Quality varies more than in Western markets, so due diligence is non-negotiable: facility inspection history, the relevant regulatory approvals for your target market, and quality-system maturity should drive selection. The upside — cost, scale, and a vast pool of FDA-inspected sites — is unmatched for the right program.
How this list is built: companies appear here when they have a manufacturing site in India in our facilities dataset and pass the marketplace eligibility gate (pharmaceutical contract manufacturers only — CROs, equipment suppliers, and other non-manufacturers are excluded). Read the full methodology for the eligibility gates and how our ranked lists are computed.
Our AI Matchmaker analyzes your project requirements and matches you with qualified India manufacturing partners. Free for buyers.